Neuland Laboratories Ltd.
NSE: NEULANDLABNeuland Laboratories Ltd.: A 30-second snapshot
NEULANDLAB trades around ₹19,202, up 38.65% over the past year and 18.72% over three months, sitting 4.24% below its 52-week high and above both its 50-DMA (₹17,958.69) and 200-DMA (₹15,659.35) with RSI at a neutral 58.1. Trailing PE of 67.0 ranks 5th of 6 tracked Pharma peers on valuation, while forward PE of 41.86 reflects the market's built-in earnings-growth expectation.
P/E
67.0
Forward P/E
41.9
ROE
—
Debt / Equity
16.07
Profit Margin
+2.3%
Div. Yield
+0.2%
5Y ROE > 15%
4/5
5Y FCF > 0
3/5
Quality
65/100
Recent context
- ·No headlines were retrieved in this run (news sentiment total = 0), so there is no recent news-driven catalyst captured for this cycle.
- ·Price is up 18.72% over the past 3 months and sits 4.24% below its 52-week high, with RSI at a neutral 58.1.
- ·Trailing PE of 67.0 compares with a forward PE of 41.86, reflecting the earnings growth the market currently has priced in.
Strengths
- +Price sits above both the 50-DMA (₹17,958.69) and 200-DMA (₹15,659.35), up 38.65% over 1 year and 18.72% over 3 months, only 4.24% below the 52-week high.
- +ROE above 15% in 4 of the last 5 years and free cash flow positive in 3 of 5 years, per the persistence data (consistency score 78).
- +5-year revenue growth of 136.4% and 5-year earnings growth of 664.4%.
- +Mean analyst rating of 1.0 across 4 analysts (1–5 scale, lower = more constructive).
Weaknesses
- −Net profit margin of just 2.29%, thin relative to the scale of five-year growth (136.4% revenue, 664.4% earnings).
- −Trailing PE of 67.0 ranks 5th of 6 tracked Pharma peers (2nd-most expensive after Max Healthcare's 74.6), well above Cipla (35.4), Dr. Reddy's (28.9) and Sun Pharma (41.6).
- −Debt-to-equity is roughly 0.16x and the persistence data marks the trend as 'rising' — the absolute level remains low for a non-financial company, but the direction is worth tracking.
- −Current-period ROE and analyst coverage (4 analysts) are both limited, constraining how precisely capital efficiency and consensus view can be benchmarked this cycle.
Open questions
- ?Does the 'rising' debt-to-equity trend reflect capacity expansion or capex financing, given the absolute level remains low at roughly 0.16x?
- ?How sustainable is the 2.29% net margin if revenue growth normalizes from the current 136.4% five-year pace?
- ?What explains the valuation gap between NEULANDLAB's PE of 67.0 and lower-multiple peers like Dr. Reddy's (28.9) and Cipla (35.4) — growth expectations, niche positioning, or something else?
- ?With analyst coverage limited to just 4 names, how much weight should be placed on the consensus rating relative to independent review of the fundamental and technical data?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| NEULANDLAB | Neuland Laboratories Ltd.You're viewing | 67.0 | — | 46 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹19,202.00
SMA 50
₹17,958.69
SMA 200
₹15,659.35
RSI (14)
58.1 (neutral)
From 52w high
-4.2%
1Y return
+38.6%
3M return
+18.7%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumNet profit margin is 2.29%, thin relative to the scale of five-year revenue growth (136.4%) and earnings growth (664.4%) — the absolute profitability cushion is narrow compared with the growth headline numbers.
- mediumTrailing PE of 67.0 ranks 5th of 6 tracked Pharma peers (2nd-most expensive, behind only Max Healthcare at 74.6), while Cipla (35.4), Dr. Reddy's (28.9) and Sun Pharma (41.6) trade at meaningfully lower multiples.
- mediumZero news headlines were retrieved in this run (news.sentiment.total = 0), so no recent-event context is available for this analysis cycle.
- lowCurrent-period ROE is not available and analyst coverage is limited to 4 analysts, both of which constrain how precisely capital efficiency and consensus view can be benchmarked against peers this cycle.
Cross-section contradictions
- NEULANDLAB ranks 5th of 6 sector peers on PE (more expensive) while ranking 2nd of 6 on qualityScore (46) — the stock is priced above most peers even though the composite quality metric places it in the upper half of the tracked set.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days